Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is a monoclonal antibody presented as a subcutaneous formulation for injection use. It modulates immune activity and is indicated for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease in adult patients.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable cold‑chain logistics for biologic products across multiple continents and therapeutic areas, with dedicated technical support for healthcare providers.

Ustekinumab is a monoclonal antibody that targets interleukin‑12 and interleukin‑23 pathways, used in several immune‑mediated inflammatory conditions. - Plaque psoriasis: decreases erythema, scaling and plaque thickness, leading to clearer skin and improved quality of life. - Psoriatic arthritis: alleviates joint pain and swelling, improves physical function, and may slow radiographic progression. - Crohn's disease: promotes mucosal healing, reduces abdominal pain and diarrhea, and helps maintain long‑term remission.

Ustekinumab may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory infections: nasopharyngitis, sinusitis, or mild cough. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. Serious or Rare Side Effects: - Serious infections: tuberculosis, opportunistic fungal or bacterial infections. - Hypersensitivity reactions: anaphylaxis, angioedema, or severe rash. - Malignancies: rare reports of lymphoma or skin cancer. - Cardiovascular events: rare cases of myocardial infarction or stroke.

Before initiating therapy with Ustekinumab, clinicians should consider several precautionary measures. - Screening: Assess for active infections, including tuberculosis, before starting treatment. - Vaccination: Administer necessary vaccines prior to therapy; avoid live vaccines during treatment. - Monitoring: Regularly monitor for signs of infection, malignancy, and laboratory abnormalities. - Pregnancy: Use only if potential benefit justifies potential risk; data are limited. - Concomitant immunosuppression: Evaluate need for additional immunosuppressants to minimize infection risk. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab can interact with other medicines, influencing efficacy or safety. Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection; avoid administration while on therapy. - Immunosuppressants: combined use with potent agents (e.g., azathioprine, methotrexate) may increase infection risk; requires close clinical judgment. Moderate Interactions (Monitor Closely): - Cytochrome P450 substrates: Ustekinumab does not significantly affect CYP enzymes, but monitor drugs with narrow therapeutic windows. - Antifungal agents: co‑administration may require monitoring for additive immunosuppression. - Anticoagulants: watch for bleeding risk if severe infection occurs.